Dr. Venter and the SGI team, as world leaders in developing and driving this area of science, also believe that addressing the societal and ethical issues surrounding synthetic genomics are essential aspects in conducting this research. As such, he and the team have spent equal time focused on these issues in conjunction with and as an augment to the considerable work that has been done at JCVI since 1995. The research at JCVI has undergone significant review at the highest levels of science and government and SGI supports continued review and discussion of this growing area of science. Dr. Venter and the team have met with Congressional members several times since the company's formation to educate them on the field of synthetic genomics. They have also conducted tours and outreach to state and local governments, have made presentations to many governmental agencies, and speak regularly to other groups (lay audiences, scientific groups, media, etc).
SGI has funded the work at JCVI in exchange for exclusive assignment of intellectual property rights. SGI has filed 13 patent application families on the unique synthetic genomics inventions of the JCVI team. SGI believes that intellectual property is important in the synthetic genomics/biology space as it is one of the best means to ensure that this important area of basic science research will be translated into key commercial products and services for the benefit of society. SGI intends to provide licenses to its synthetic genomics intellectual property.
|SOURCE Synthetic Genomics Inc.|
Copyright©2010 PR Newswire.
All rights reserved